A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Prior treatment

• Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy;
• Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions
  • The above is a summary, other exclusion criteria details may apply.

Other illness

• CNS pathology including but not limited to any history of seizure disorder/epilepsy;
• History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS;
• Active and uncontrolled infections;

Other

• Any neoplasm histology not specified in the IC section;
• Active CNS involvement in lymphoma;

• ≥18 years of age;
• Histologically documented CD20+ mature B-cell neoplasm
  • Large B-cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma
• Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy;
• ECOG performance status of ≤ 2 (\< 2 in EU countries).
  • The above is a summary, other inclusion criteria details may apply.